THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 125 filers reported holding THERAVANCE BIOPHARMA INC in Q3 2022. The put-call ratio across all filers is 0.59 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $702,983 | -17.3% | 81,458 | -0.9% | 0.09% | -23.9% |
| Q2 2023 | $850,335 | -4.8% | 82,158 | -0.2% | 0.12% | -3.3% |
| Q1 2023 | $893,617 | -3.3% | 82,361 | +0.0% | 0.12% | -19.3% |
| Q4 2022 | $923,653 | +11.6% | 82,322 | +0.8% | 0.15% | +20.0% |
| Q3 2022 | $828,000 | -41.5% | 81,658 | -47.7% | 0.12% | 0.0% |
| Q2 2022 | $1,415,000 | -23.2% | 156,131 | -19.0% | 0.12% | -21.4% |
| Q1 2022 | $1,842,000 | +49.6% | 192,701 | +73.0% | 0.16% | +69.1% |
| Q4 2021 | $1,231,000 | +27.0% | 111,379 | +104.3% | 0.09% | +44.6% |
| Q4 2020 | $969,000 | -0.8% | 54,522 | -17.5% | 0.06% | 0.0% |
| Q3 2020 | $977,000 | +89.0% | 66,061 | +168.4% | 0.06% | +85.7% |
| Q2 2020 | $517,000 | +166.5% | 24,614 | +39.2% | 0.04% | +775.0% |
| Q3 2015 | $194,000 | -65.3% | 17,683 | -58.8% | 0.00% | -73.3% |
| Q2 2015 | $559,000 | +96.8% | 42,927 | +161.9% | 0.02% | +114.3% |
| Q1 2015 | $284,000 | – | 16,393 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Madison Avenue Partners, LP | 7,012,226 | $60,515,510 | 8.59% |
| Irenic Capital Management LP | 2,760,948 | $23,826,981 | 6.76% |
| Newtyn Management, LLC | 1,841,560 | $15,892,663 | 3.92% |
| Weiss Asset Management LP | 7,457,060 | $64,354,428 | 3.81% |
| Park West Asset Management LLC | 1,983,251 | $17,115,456 | 1.57% |
| Baupost Group | 7,419,226 | $64,028 | 1.23% |
| Oasis Management Co Ltd. | 953,254 | $8,226,582 | 0.36% |
| Chescapmanager LLC | 287,333 | $2,479,684 | 0.32% |
| GSA CAPITAL PARTNERS LLP | 325,985 | $2,813 | 0.24% |
| Virtus ETF Advisers LLC | 29,232 | $252,272 | 0.15% |